01 Nov Exact Sciences study shows new cancer markers could improve screening test
Recent study results from Exact Sciences show that newly identified markers for colon cancer could improve the company’s Cologuard test.
The Madison-based cancer diagnostics company is partnering with the Mayo Clinic on research aimed at improving the precision of the test, which relies on stool samples rather than an invasive exam.
That work hinges on new biomarkers, or clues indicating the presence of cancer or precancerous growths known as adenomas. The new markers were more accurate than the current test on the market.
The findings were presented earlier this week at the annual meeting for the American College of Gastroenterology. Company Chairman and CEO Kevin Conroy says an improved test is in the works.
Sorry, the comment form is closed at this time.